You are here

dasatinib

BDR Pharma seeks India license for Bristol-Myers drug

Reuters

Mon, 03/18/13 - 11:00 am

Bristol-Myers Squibb

SPRYCEL(R) (dasatinib) Demonstrates Superior Confirmed Complete Cytogenetic Response Rates Compared to Gleevec(R)* in Study of Adult Patients with Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase

BusinessWire

Sat, 06/5/10 - 12:24 pm

chronic myeloid leukemia